Keywords
Citation
(2012), "Imaging in Parkinson’s Disease", International Journal of Health Care Quality Assurance, Vol. 25 No. 1. https://doi.org/10.1108/ijhcqa.2012.06225aaa.012
Publisher
:Emerald Group Publishing Limited
Copyright © 2012, Emerald Group Publishing Limited
Imaging in Parkinson’s Disease
Imaging in Parkinson’s Disease
Article Type: Recent publications From: International Journal of Health Care Quality Assurance, Volume 25, Issue 1
David EidelbergOUP USAISBN: 978-0-19-539348-42011
Keywords: Parkinson Disease management, Imaging methodology, Disease diagnosis
Imaging in Parkinson’s Disease provides up-to-date information concerning new applications of brain imaging to the study of Parkinson’s disease. Written by experts in the field, the book focuses on structural and functional imaging methodologies that have recently been applied to study the natural history of Parkinson’s disease, with emphasis on the development of the major motor manifestations of the illness as well as cognitive impairment and dementia. Individual chapters address the role of imaging in differential diagnosis and in the evaluation of pharmacologic and surgical treatment effects. In-depth discussion of the use of imaging tools to study disease mechanisms is also provided, with emphasis on the roles of neuroinflammation, protein aggregation, and abnormal network organization in parkinsonism. Additionally, the text covers a number of relevant novel topics including recent advances in volumetric and functional MRI, echosonography, dopaminergic and cholinergic neurotransmitter imaging, and applications to experimental interventions such as gene therapy and transplantation.
Covering a wide range of subjects and beautifully illustrated, Imaging in Parkinson’s Disease is a valuable reference for neurologists, neurosurgeons and neuropsychologists, and a helpful resource for students engaged in postgraduate biomedical and clinical training.
Contents include:
- •
Dopaminergic imaging in Parkinson’s DiseaseD: PET.
- •
Dopaminergic imaging in Parkinson’s DiseaseD: SPECT.
- •
Cerebral glucose metabolism and blood flow in Parkinson’s Disease.
- •
Structural abnormalities in Parkinson’s Disease: MRI and related methods.
- •
Transcranial sonography in Parkinsonian Syndromes.
- •
Parkinsonian tremor.
- •
Atypical Parkinsonian syndromes.
- •
Brain activation studies in Parkinson’s Disease.
- •
Functional markers of cognition in Parkinson’s Disease: 18F-FDG and H215O Positron emission tomography studies.
- •
Imaging cognitive dysfunction in Parkinson’s Disease: cholinergic neurotransmission and protein aggregation.
- •
Imaging inflammation in Parkinsonian Syndromes.
- •
Functional imaging biomarkers for the assessment of Parkinson’s Disease progression.
- •
Effects of treatment.
- •
Neuroimaging in Levodopa induced Dyskinesia.
- •
Effects of surgical treatment.
- •
Cell-based therapies: imaging outcomes.
- •
Imaging applications to Parkinson’s Disease clinical trials.
- •
Clinical applications.